Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib.

@article{Zinke2010ImmunologicalPI,
  title={Immunological persistence in 4-6 and 7-9 year olds previously vaccinated in infancy with hexavalent DTPa-HBV-IPV/Hib.},
  author={Michael Zinke and Johann Disselhoff and Britta Gartner and J M Jacquet},
  journal={Human vaccines},
  year={2010},
  volume={6 2},
  pages={
          189-93
        }
}
BACKGROUND The combined diphtheria-tetanus-pertussis-hepatitis B-inactivated poliomyelitis-Haemophilus influenzae conjugate vaccine (DTP a-HBV-IPV/Hib, Infanrix Hexa() GlaxoSmithKline Biologicals, Rixensart, Belgium) is the only hexavalent vaccine currently licensed for primary and booster vaccination of infants and provides simultaneous protection against six major diseases of childhood. The persistence of the immune response in children aged 4-6 and 7-9 years of age previously vaccinated with… CONTINUE READING
BETA

Similar Papers

Citations

Publications citing this paper.
SHOWING 1-10 OF 10 CITATIONS

DTPa-HBV-IPV/Hib Vaccine (Infanrix hexa™)

VIEW 6 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Pertussis Persistence in Ontario

VIEW 1 EXCERPT
CITES BACKGROUND